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Abstract. The increasing shortage of organs for transplantation has prompted transplant programs to investigate the
use of extended criteria donors, such as those with transmissible infectious diseases. Successful cases of organ
transplantation (mostly kidney and liver) from Trypanosoma cruzi seropositive donors to seronegative recipients have
been reported. We present a case of lung transplantation from a donor serologically positive for Chagas disease to a sero-
negative recipient, and provide a review of the literature. Left single lung transplantation was performed in a 44-year-old
Spanish woman presenting with interstitial lung disease in February 2016. The deceased donor was a Colombian
immigrant living in Spain who was serologically positive for Chagas disease. Oral administration of 5 mg/kg/day benz-
nidazole divided in three doses for 60 days was given for specific Chagas disease prophylaxis after transplantation.
Periodic follow-upwith serological reverse transcriptionpolymerase chain reaction todetectT. cruziDNAwereperformed
until 6 months after the end of treatment. All results were negative, indicating that transmission of T. cruzi had not
occurred. In a review of the literature, two similar cases were identified in Argentina and the United States. In both cases
T. cruzi infection was detected posttransplant in the recipients, after which they were treated with benznidazole. The
course of the patient described herein confirms that lungs from donors with chronic T. cruzi infection can be used
successfully as allografts, and that posttransplant prophylaxis with benznidazole may reduce the probability of trans-
mission of T. cruzi to the recipient.
INTRODUCTION
Chagas disease is a parasitic infection endemic in all the
countries of Central and South America as well as in Mexico,
which is caused by the hemoflagellated protozoan Trypano-
soma cruzi. Is estimated that 6–7 million people are infected
worldwide, and 10,000 people die annually mostly due to
chagasic cardiomyopathy.1 The main transmission routes are
through hematophagous triatomine vectors and congenitally
from mother to child, but the parasite also can be acquired
through other routes, such as blood transfusion and organ
transplantation from infected donors, laboratory accidents,
and by consumption of contaminated food and drink.2
In recent years, the increasing shortage of organs for
transplantation has prompted transplant programs to in-
vestigate the use of extended criteria donors, such as those
with transmissible infectious diseases.3 Acute Chagas dis-
ease in anorgandonor is anexclusioncriterion, and in addition
transplantation of the heart or intestines from a donor with any
stage of T. cruzi infection is not recommended.4 However,
successful cases of transplantation of other organs (mostly
kidney and liver) from T. cruzi seropositive donors to sero-
negative recipients have been reported with close post-
operative monitoring and benznidazole treatment.5–10
In this report, we describe our experience with lung trans-
plantation from a donor serologically positive for Chagas
disease to a seronegative recipient, and provide review of the
literature.
CASE REPORT
Left single lung transplantation was performed in a
44-year-old Spanish woman in February 2016. The patient
presented with interstitial lung disease (desquamative in-
terstitial pneumonitis) diagnosed on June 2013, and was
receiving treatment with corticosteroids, mycophenolate, and
homeoxygen therapyduring themonthsbefore transplantation.
The deceased donor was an immigrant from Colombia living in
Spain who was serologically positive for Chagas disease, as
assessed by an enzyme-linked immunosorbent assay (ELISA)
based on recombinant antigen (Bioelisa Chagas, Biokit, Lliça`
d’Amunt, Spain), and an ELISA based on a whole cell lysate
(Ortho T.cruziELISA, Johnson and Johnson, HighWycombe,
UK) at the moment of donation; hence treatment with benz-
nidazole was not performed before transplantation. The
recipient was aware of the risk of transmission of Chagas
disease and provided written informed consent for the
procedure.
The patient’s immunosuppressive treatment included
tacrolimus adjusted to a target blood level of 7–10 ng/mL,
mycophenolate mofetil in conventional doses, and cortico-
steroids. The patient had several postoperative complica-
tions: grade 3 primary graft dysfunction, multiorganic failure,
left radial artery thrombosis, critical illness myopathy and
polyneuropathy, gastroparesis, Candida albicans catheter-
related bloodstream infection, and urinary tract infection by
Enterococcus faecium.
On day 16 posttransplantation, after resolution of the mul-
tiorganic failure, oral administration of 5 mg/kg/day benz-
nidazole divided in three doses for 60 days was begun for
specific Chagas disease prophylaxis. There were no relevant
adverse events, and modification of the doses of immuno-
suppressive drugs was not required. The recipient was
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monitored for evidence of T. cruzi infection after the transplant
by serological testingwith theassaysmentionedearlier andby
reverse transcription polymerase chain reaction (RT-PCR) as
describedbyPiron andothers.11 Thismonitoring protocolwas
startedon the dayof the transplant andcontinuing onaweekly
basis through the end of the 60-day course of benznidazole,
andonamonthly basis thereafter. All serological tests andRT-
PCR during follow-up were negative (see Table 1); thus there
was no evidence that transmission of T. cruzi from donor to
recipient had occurred.
The patient had a hospital stay of 113 days (73 days in
intensive care and 40 days on a thoracic surgery ward) and at
11 months posttransplantation the patient was doing well,
although intermittent home oxygen therapy was still required
because of desaturation with moderate exercise.
LITERATURE REVIEW
We identified previous cases of lung transplantation from
seropositive Chagas disease donor to seronegative recipient
using a MEDLINE search, with the terms “Trypanosoma cruzi
infection AND lung transplantation,” “Chagas disease AND
lung transplantation,” with no restriction regarding language
or date of publication.
Two additional cases were identified. The first case was
described by Cura and others in Argentina in 2013.12 Lung
transplantation was performed from a 58-year-old Argenti-
nean donor with positive Chagas disease serology to a
57-year-old man. The recipient was monitored with serial se-
rological studies and direct parasitological techniques (PCR,
and Strout technique). On day 72 following transplantation,
parasitemia was demonstrated by PCR, the Strout technique
was positive on day 119, and the serological tests on day 210,
and the patient was given 5 mg/kg/day benznidazole for
60 days, starting on day 126 after transplantation. The patient
did not presented any clinical manifestations associated to
the acute infection, and direct diagnosis techniques turned
negative during treatment and remained so for at least
239 days after transplantation.
The second case was described by Huprikar and others in
the United States in 2013.13 Bilateral lung transplantation was
performed from a 48-year-old female donor from El Salvador
with positive Chagas disease serology to a 36-year-old man
who had cystic fibrosis. Immunosuppression included pred-
nisone, mycophenolate, and tacrolimus. The recipient was
monitored for T. cruzi infection with PCR, hemoculture, and
trypomastigote excreted-secreted antigens immunoblot.
Unfortunately all three assays turned positive in weeks 29 and
30. The patient was asymptomatic and received treatment
with benznidazole for 60 days. By week 43, the results of se-
rologic and PCR testing were negative. However, at 61 and
63 weeks after transplantation, PCR was positive again, and
second course of treatment was given.
DISCUSSION
In this study,wepresent the successful lung transplantation
from a T. cruzi seropositive donor to a seronegative recipient,
towhomprophylactic treatment with benznidazole was given,
and who was followed with repeated testing for evidence of
T. cruzi transmission, which was constantly negative. To the
best of our knowledge, this is the third reported case of lung
transplantation with Chagas disease seropositive donor, and
the first one in a European country.
Transmission of Chagas disease and development of
the acute form of the disease has been previously described
following solid organ transplantation, mostly in kidney re-
cipients.14,15 Acute form or reactivation of Chagas disease in
immunosuppressed patients (human immunodeficiency
virus-infected patients, transplant recipients) may result in
high parasitemia and severe clinical manifestations, such as
meningoencephalitis, acute myocarditis, and skin lesions.16
The risk of developing these clinical complications post-
transplant underscore the importance of the screening for
Chagas disease both in solid organ donors and recipients
coming from endemic areas; hence, different expert groups
have elaborated consensus documents to address this is-
sue.3,4,17 Notwithstanding, no national legislation regarding
solid organ transplantation in European countries includes
Chagas disease as a specific topic; only three national trans-
plant organizations (from Italy, Spain, and the United Kingdom)
have included a specific section regarding how to control
transmission of Chagas disease through donor screening.18
The economic stagnation in some Latin American countries
endemic for Chagas disease have stimulated the flow of mi-
gration todevelopedcountries during recent decades,making
Chagas disease a global health problem.19 After the United
States, Spain is the second most affected country, and Cha-
gas disease is increasingly being diagnosed in immigrant
populations coming from endemic areas; however, it is esti-
mated that 95%ofT. cruzi-infectedpersons living in European
countries remain undiagnosed.20,21 These migration flows
from Chagas disease endemic countries to the United States
and European countries has contributed that Chagas disease
patients are increasingly receiving different immunosuppres-
sive therapies and participating in transplant programs (both
as a donors and recipients), so that Chagas disease and im-
munosuppression coexistence is being reported increasingly
in nonendemic countries.22,23
TABLE 1













+5 0.09 0.16 Negative
+15 0.06 0.11 Negative
+16 Onset of benznidazole treatment
+24 0.02 0.11 Negative
+29 0.08 0.17 Negative
+36 0.12 0.42 Negative
+44 0.19 0.33 Negative
+53 0.28 0.26 Negative
+59 0.30 0.30 Negative
+66 0.61 0.35 Negative
+75 0.44 0.44 Negative
+78 End of benznidazole treatment
+80 0.5 0.39 Negative
+109 0.5 0.22 Negative
+148 0.68 0.37 Negative
+173 0.61 0.17 Negative
+208 0.61 0.33 Negative
+235 0.58 0.42 Negative
ELISA=enzyme-linked immunosorbent assay;RT-PCR= reverse transcriptionpolymerase
chain reaction.
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As mentioned previously, the shortage of organs for trans-
plantation has stimulated transplantation programs the use of
“extended criteria donors,” such as those with Chagas dis-
ease. In this situation, two different strategies have been
proposed: the prophylactic treatment (treatment with benz-
nidazole or nifurtimox is administered to the recipient as soon
as possible after transplantation) and the preemptive treat-
ment (treatment is only administered if transmission of the
infection is detected sometime during the posttransplant
period). Even though the use of benznidazole as a prophy-
lactic treatment remains controversial due to its safety profile,
we opted for this strategy based on the higher Chagas disease
transmission rate described with the preemptive strategy, and
based in our own experience in liver transplantation.5–10 It is
remarkable that our patient did not have any of the side effects
typically associated with benznidazole, and apparently that
there were no untoward interactions with the immunosup-
pressive drugs she was concurrently receiving.
The risk of Chagas disease transmission through organ
transplantation may also depend on the transplanted organ.
Taking into account the main studies about organ trans-
plantation with T. cruzi seropositive donors to seronegative
recipients, transmission of Chagas diseasewas 66.6% in lung
transplantation (two out of three; our case and the two pre-
viously reported), 27.3% in liver transplantation (nine out of
33), and 14.9% in kidney transplantation (seven out of
47).5–10,12,13 These differences could be due to the amount
of blood contained in the transplanted organ or to infected
cells in the organ itself.
Regardless of the strategy used (prophylactic versus pre-
emptive), a close follow-up is essential to detect disease
transmission as early as possible. Acute infection by organ
transplantation transmission must be diagnosed through
classical parasitological techniques, such as the Strout
technique, microhematocrit, or hemoculture.24 However,
these techniques are tedious and require considerable skill.
Fortunately, however, PCR is often used in these situations,
and it offers the advantages of quick turnaround and relatively
high sensitivity.5,25,26Moreover, real-time techniques (such as
RT-PCR) may add quantitative results, which could improve
monitoring these patients.
In summary, we present a case of lung transplantation from
a T. cruzi seropositive patient to a seronegative recipient, with
no evidence of disease transmission after prophylactic treat-
ment with benznidazole and close posttransplant monitoring.
We stress the importance of screening for Chagas disease in
all donors and recipients coming from endemic areas. The
course of the patient described herein confirms that lungs
from donors with chronic T. cruzi infection can be used suc-
cessfully as allografts, and that posttransplant prophylaxis
with benznidazole may reduce the probability of transmission
of T. cruzi to the recipient, which should be sought through
close monitoring with serologic assays and PCR.
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